FF 21101 Y-90

Drug Profile

FF 21101 Y-90

Alternative Names: FF 21101-Y-90; FF-21101; FF-21101(90Y)

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer FUJIFILM Holdings Corporation; Strategia Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Cadherin inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Apr 2017 Interim adverse events, efficacy and pharmacokinetics data from a phase I trial in solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Jan 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Parenteral) (NCT02454010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top